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Background: Epithelial ovarian cancer is one of the most lethal gynecologic malignancies. Clinicopathological
factors do not permit precise prognosis and cannot provide guidance to specific treatments. In this study we
assessed tumor infiltrating CD8+ T cells in association with Ki67 proliferation index and evaluated their prognostic
impact in EOC samples.
Methods: CD8+ cells and Ki67 proliferation index were immunohistochemically determined on tissue microarrays
including 203 primary epithelial ovarian tumors. Additionally, CD8 gene expression was assessed with RT-qPCR.
Correlations were analyzed using Pearson’s correlation coefficients, ANOVA or T-test, or Fischer’s exact tests.
Prognostic impact was evaluated using the Kaplan-Meier method and Cox regression model.
Results: The density of CD8+ infiltrating lymphocytes did not correlate with tumor cell proliferation. Epithelial
ovarian cancer patients with no Ki67+ cells in the tumor had a more than three times higher risk to die compared
to the population with Ki67+ cells in the tumor (Hazard ratio (HR) = 3.34, 95%CI 1.59-7.04). High CD8+ cell
infiltration was associated with improved overall survival (HR = 0.82, 95%CI 0.73-0.92).
Conclusions: The density of tumor infiltrating lymphocytes is independent of tumor cell proliferation. Ovarian
cancer patients with Ki67- tumors showed a significantly reduced overall survival, presumably due to no or poor
response to platinum-based chemotherapy. Moreover, the association of high densities of tumor infiltrating
cytotoxic T lymphocytes with a better overall survival was confirmed.
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Epithelial ovarian cancer (EOC) is one of the most lethal
gynecologic malignancies with 67,000 new cases and
42,000 deaths in Europe per year [1]. Despite increasing
knowledge in the etiology of ovarian cancer and the im-
provements in surgery and chemotherapy, there has been* Correspondence: dan.cacsire-castillo@meduniwien.ac.at
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distribution, and reproduction in any mediumlittle change in the survival of patients. Clinicopathological
factors do not permit precise prognosis for the disease and
thus cannot provide guidance to specific treatments.
Proliferation is one of the most important hallmarks of
cancer and has been reported to have impact on progno-
sis in various malignancies. High cell proliferation, deter-
mined mostly by biomarkers such as Ki67, has been
correlated with occurrence of metastases and subsequent
worse clinical outcome for melanoma patients [2]. In con-
trary, in colorectal and gastric cancer, Ki67 has also been
associated with improved overall survival and relapse-free
survival [3,4]. In ovarian cancer, Ki67 proliferation index
has been associated with advanced stage, high grade andd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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has also been reported as independent prognostic factor
for poor overall and progression-free survival [5-7].
Infiltrating lymphocytes are frequently found in tumor
tissues, indicating an ongoing host immune response. The
prognostic value of tumor infiltrating lymphocytes on the
clinical outcome has been assessed in a variety of cancer
entities [8-10]. Various studies have reported a survival ad-
vantage associated with the presence of tumor infiltrating
T cells (CD3) and cytotoxic T cells (CD8) [11]. However,
other studies revealed a non-significant prognostic value of
CD3+ and/or CD8+ T lymphocytes [10,12,13]. In EOC,
tumor infiltrating CD8+ cells have been described to play a
major role in antitumoral activity and survival [14-17].
We hypothesize that the outcome of cancer patients is
a result of interactions of tumor cell proliferation and
host immune reaction. The proliferative potential of tu-
mors may influence leukocyte infiltration. In breast can-
cer, CD8+ T cells were found to be less abundant in the
tumor microenvironment of highly proliferating tumors
[18]. Another study confirmed the prognostic impact
of infiltrating lymphocytes only in rapidly proliferating
breast cancer tissues [19]. For EOC, the association of
cancer cell proliferation and host immune response has
seldom been addressed.
In this study, we assessed tumor infiltrating CD8+ T
cells as one of the important factors in the adaptive im-
mune system in association with Ki67 expression that
reflects the tumor proliferation by immunohistochemis-




203 patients with epithelial FIGO stage II to IV ovarian
cancer from OVCAD (FP6 EU-project, Ovarian Cancer:
Diagnosis of a silent killer, no. 018698, www.ovcad.eu) were
included in the study. Patients have been recruited from
2005 to 2008 in the Department of Gynecology at Charité,
Campus Virchow-Klinikum, Medical University Berlin,
Germany (64); Department of Obstetrics and Gynecology
and Gynecologic Oncology, University Hospital Leuven,
Belgium (54); Department of Gynecology, University Med-
ical Center Hamburg-Eppendorf, Germany (38); Depart-
ment of Obstetrics and Gynecology, Medical University
of Vienna, Austria (37); Department of Gynecology and
Obstetrics, Innsbruck Medical University, Austria (10).
Informed consents were obtained from all patients. All
processes were approved by the respective local ethical
committee (EK207/2003, ML2524, HEK190504, EK366,
EK260). Patients were treated with cytoreductive surgery
and platinum-based chemotherapy. Tumor tissues were
obtained during primary surgery and before any chemo-
therapeutic treatment. Residual tumor load was defined asnegative if macroscopically absent. Overall survival (OS)
was defined as the time from diagnosis to death from
any disease-related cause. The survival times of patients
alive at their last follow-up visit were treated as censored.
Progression-free survival (PFS) was defined as the time
from diagnosis until progression of disease, censoring pa-
tients who were recurrence-free at their last follow-up visit,
and excluding patients with refractory disease, defined as
progression of disease while receiving first line platinum-
based therapy or within four weeks of the last platinum
application [20]. Progression was defined by radiological
diagnosis according to the RECIST criteria or as doubling
of the nadir serum CA-125 [21]. Experienced gynecological
oncologists and pathologists performed the clinical and
histopathological evaluations.
Tissue microarray
Tissue microarrays (TMA) were assembled using two
one mm2 tissue cores of the same primary tumor tissue
block per patient. For each tissue sample, representa-
tive tumor areas were marked on the hematoxylin-eosin-
stained section. The cores were punched from different
selected areas of each sample using a tissue micro-
arrayer (Beecher Instruments, Woodland, CA, USA) and
embedded in a new paraffin block. Regarding tumour infil-
trating CD8+ cells, the mean value of the two TMA cores
were confirmed to be representative of the whole tumour
tissue [22].
Immunohistochemistry
Antigen heat retrieval was performed by microwaving
the slides for 15 minutes in EDTA (1 mM, pH 8.0) and
Dako Target Retrieval Solution (Dako, Denmark) for
the CD8 and Ki67 staining, respectively. Slides were
then cooled to room temperature and quenched for en-
dogenous peroxidase. Blocking solution (Ultra V Block;
TA-015HP, Thermo Fisher Scientific, USA) was applied
prior to incubation with monoclonal mouse antibodies
against CD8 (1:1000; clone C8/144B, code M 7103, Dako,
Denmark) and Ki67 (1:75, clone MIB-1, code M7240,
Dako, Denmark) overnight at 4°C. UltraVision detection
system (Thermo Fisher Scientific, USA) and the Dako
LSAB System (Dako, Denmark) were used for CD8 and
Ki67, respectively, according to the manufacturers’ in-
structions. The CD8 stained sections were incubated with
Primary Antibody Enhancer (TL-015-PB, Thermo Fisher
Scientific, USA), followed by horseradish peroxidase (HRP)
Polymer (HRP Polymer; TL-015-PH, Thermo Fisher Scien-
tific, USA); for Ki67 staining, Dako Biotinylated Link
(K0675, Dako, Denmark), followed by Dako Streptavidin-
HRP (K0675, Dako, Denmark) was applied. The slides were
stained with diamino-benzidine (DAB, 1:50 in DAB Sub-
strate Buffer, K0673, Dako, Denmark) and counterstained
with hematoxylin. Lymph node and normal colon tissue
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Ki67, respectively. Mouse IgG1 (1:75; Negative Control
Mouse IgG1, code X0931, Dako, Denmark) was used as
isotype control.
Slides were digitally photographed with the TissueFAXS
system (version 2.0.4.0147, TissueGnostics, Austria) using
an x20 objective lens. HistoQuest software (version
3.0.3.0161, TissueGnostics, Austria) was used for the detec-
tion and quantification of CD8+ cells. The TissueFAXS de-
tection and quantification method was recently applied in
other human cancer entities [23] and is based on tech-
niques described and validated by Steiner et al. [24]. The
CD8+ cell density (cells/mm2) was determined only in epi-
thelial tumor tissue. To avoid false positive cell counting, a
specific gate according to cell size and intensity of CD8
staining was set within which the cells were considered
positive. These cells were randomly controlled by applying
a function permitting the visualization of the correspond-
ing cells on the digital picture.
Scoring of the Ki67 proliferation index was evaluated
manually by two independent observers determining the
percentage of Ki67+ cells in total epithelial tumor tissue.
RNA extraction, cDNA synthesis and qPCR
Tumor tissues from 158 out of the 203 patients were avail-
able. About 30 mg fresh frozen tumor tissue was homoge-
nized using a Mikro-Dismembrator U (B. Braun, Biotech
International, Germany) and lysed in one ml Nucleic Acid
Purification Lysis Solution (Applied Biosystems, Life Tech-
nologies, USA). Total RNA from the lysates was iso-
lated with the ABI PRISM 6100 Nucleic Acid PrepStation
(Tissue RNA isolation, Applied Biosystems, Life Tech-
nologies, USA) and quantified spectrophotometrically.
The quality of RNA was assessed with an Agilent 2100
Bioanalyzer. RNA with an RNA Integrity Number >5
was used.
The cDNA synthesis was performed with the Omniscript
Reverse Transcription Kit (QIAGEN, Netherlands) with
500 ng RNA according to manufacturer’s instruc-
tions. cDNA was diluted 1:2 with TE buffer and de-
posited at −80°C for further analysis. The qPCR was
performed with the CD8ATaqMan Gene Expression Assay
(Hs00233520_m1, Applied Biosystems, Life Technologies,
USA) according to the manufacturer’s instructions. As a
reference, gene expression of house-keeping gene GAPDH
(Hs99999905_m1, Applied Biosystems, Life Technologies,
USA) was measured. 2 μl cDNA, 0.4 μl TaqMan Gene
Expression Assay, 4 μl 2x TaqMan Gene Expression
MasterMix (Applied Biosystems, Life Technologies, USA)
and 1.6 μl H2O were used. The reaction mixture was pre-
incubated at 50°C for two minutes and at 95°C for ten mi-
nutes, followed by 40 cycles of two step incubation at 95°C
for 15 seconds and at 60°C for one minute. Each PCR was
performed in duplicates.Statistical analyses
Raw CD8+ cell density values were log2-transformed to
achieve normal distribution. For each patient, the mean
value of the two cores was calculated. To evaluate the
RT-qPCR data, the mean value of the duplicate expres-
sion values (Ct values) was calculated and normalized
with the mean Ct value of the reference gene GAPDH.
Differences between plates were corrected with a cali-
brator. Finally the normalized values were multiplied
by −1 to be interpretable as log2-expression (relative ex-
pression values). Statistical analyses were performed with
SPSS (version 19, Chicago, USA) and SAS (version 9.3,
2011 SAS Institute Inc., Cary, NC, USA). Correlation of
continuous variables (CD8+ cell density and relative ex-
pression values, Ki67 proliferation index and age) was
assessed by Pearson’s correlation coefficients. Continuous
variables were compared between groups by ANOVA or
T-test. The association of categorical variables was evalu-
ated by Fisher’s exact tests. Cumulative survival prob-
abilities were calculated by the Kaplan-Meier method.
Univariate and multivariable Cox proportional hazards
regression analysis was used to evaluate the marginal and
adjusted association of CD8+ cell density, percentage of
Ki67 proliferation index, CD8 relative expression values
and the clinicopathological factors age, FIGO stage and re-
sidual tumor with survival [25]. For multivariable regres-
sion, the multivariable fractional polynomial approach was
used, which evaluates possible non-linear effects of con-
tinuous variables such as CD8+ cell density or Ki67 by
a set of parsimonious transformations [26]. Because of
the relatively low number of patients with FIGO II (9),
we modeled FIGO stage as ordinal rather than categor-
ical variable, assuming the same hazard ratio between
FIGO IV and III as between FIGO III and II. This strat-
egy provides more stable results than with categorical
modeling of FIGO stage. Pairwise interactions between
CD8+ cell density and other variables were tested by
assessing significance of corresponding product terms.
Two-sided p values <0.05 were considered statistically
significant in all the analyses.
Results
Clinical outcome of the patients
Clinical and pathological characteristics of tumors of the
203 EOC patients are depicted in Table 1. The median
age at time of diagnosis was 56 years (range 18–85 years).
Median follow-up time was 48 months (25th percentile,
39 months; 75th percentile, 57 months). 12 patients (6%)
with refractory disease were excluded from PFS analyses.
95 patients (47%) died within the observation period and
139 (77%) patients had a recurrence. Median PFS was
19 months (25th percentile, 11 months; 75th percentile,
36 months) and median OS was 50 months (25th per-
centile, 25 months; 75th percentile, not reached).


















18 endometrioid, 9 mixed epithelial, 1 mucinous, 4 undifferentiated, 2 clear cell.
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lymphocytes and Ki67 proliferation index
Representative immunohistochemical staining of CD8
and Ki67 is shown in Figure 1. Intraepithelial CD8+ cells
were present in all samples with values ranging from 3 to
2,257 cells/mm2 and a median of 137 cells/mm2. In 4% of
tumors, less than ten CD8+ cells/mm2 were observed.
Log2-transformed CD8+ cell densities showed normal dis-
tribution. Ki67 proliferation indices ranged from 0% toFigure 1 Representative CD8 and Ki67 immunohistochemical staining
infiltration, respectively; C and D: high and low Ki67 proliferation index, res90% with a median of 30%. In 5% of tumors, no Ki67+ cells
were detected. The density of CD8+ infiltrating lympho-
cytes did not correlate with Ki67 proliferation index (data
not shown).Better overall survival of ovarian cancer patients with
Ki67+ tumors and high density of tumor infiltrating
CD8+ lymphocytes
Fractional polynomial modeling of the continuous factors
age, Ki67 proliferation index and the density of CD8+ cells
confirmed linearity for age and CD8, whereas a non-linear
association of Ki67 with survival was revealed. Visualizing
the shape of this non-linearity revealed that the mortality
risk was sharply increased for patients with 0% Ki67+ cells,
while it was constantly low for patients with more than
5% Ki67+ cells (Figure 2). Therefore, it is reasonable to
dichotomize Ki67 at a cutoff of 5% resulting in ten patients
with 0% Ki67+ cells (Ki67- tumors) and 190 patients
with ≥5% Ki67+ cells (Ki67+ tumors). This dichotomiza-
tion was used for OS as well as PFS analyses.
Multivariable Cox proportional-hazards regression ana-
lyses revealed age, FIGO stage, residual tumor, CD8+ cells
and Ki67 proliferation index to be significantly and inde-
pendently associated with OS. The mortality risk in-
creased by about 26% per each ten years of age (hazard
ratio (HR) = 1.26, 95% CI: 1.07-1.48) and was more than
doubled if a patient had a higher FIGO stage (IV vs. III, or
III vs. II: HR = 2.18, 95% CI 1.38-3.45). Patients with re-
sidual tumor after cytoreductive surgery had an almost
90% higher risk to die than optimally debulked patients
(HR = 1.87, 95%CI 1.21-2.88). For CD8+ cell density, the
mortality risk decreased by approximately 18% with eachin epithelial ovarian cancer. A and B: high and low CD8+ cell
pectively; optical magnification x200.
Figure 2 Non-linear association of Ki67 proliferation index
with overall survival. Association adjusted for age, FIGO,
residual tumor and CD8+ cell infiltration; relative hazard
compared to a reference level of Ki67 = 5%; X-axis indicates Ki67
proliferation index.
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with Ki67- tumors (0% Ki67+ cells) had a significantly
poorer OS than those with Ki67+ tumors (≥5% Ki67+ cells)
(HR 3.34, 95%CI 1.59-7.04, Table 2A).
For PFS, FIGO stage (HR 2.19, 95%CI 1.43-3.35) and
residual tumor (HR 1.64, 95%CI 1.11-2.43) were con-
firmed as independent prognostic factors. Ki67 prolifera-
tion index and tumor infiltrating CD8+ lymphocytes had
no significant impact on PFS (Table 2B).Table 2 Results of cox regression analyses1
A) Prognostic values of various parameters on overall survival
N = 197 (93 events) U
HR (CI95%)
Age (continuous, per decade) 1.35 (1.14-1.60
FIGO (ordinal, per stage) 2.22 (1.44-3.42
Residual tumor (yes vs. no) 2.01 (1.32-3.06
CD8+ cell infiltration (continuous, per doubling) 0.86 (0.77-0.96
Ki67+ tumor cells (<5% vs. ≥5%) 3.27 (1.57-6.83
B) Prognostic values of various parameters on progression-free surviva
N = 180 (139 events) U
HR (CI95%)
Age (continuous, per decade) 1.18 (1.03-1.34
FIGO (ordinal, per stage) 2.51 (1.72-3.67
Residual tumor (yes vs. no) 2.07 (1.44-2.98
CD8 cell infiltration (continuous, per doubling) 0.97 (0.89-1.05
Ki67 (<5% vs. ≥5%) 1.63 (0.76-3.49
1HR and p values of statistically significant parameters presented in bold.Since infiltrating CD8+ lymphocytes are removed to-
gether with the tumor mass, we assumed that their effect
might be less important in optimally debulked patients
(n = 141) compared to patients with residual tumor
(n = 62). Similarly, different benefits from surgical cyto-
reduction were observed regarding CD8+ cell tumor in-
filtration [27]. Indeed, the Kaplan-Meier curves with
dichotomized CD8+ cell infiltration values (cutoff median)
show that in non-optimally debulked patients, low CD8+
cell infiltration was associated with worse OS compared to
those with high CD8+ cell infiltration (p = 0.055, Figure 3B).
In contrast, in women without residual tumor, CD8+ cell
infiltration did not influence OS (Figure 3A). Accordingly,
univariate Cox hazard regression analysis revealed a signifi-
cant survival advantage of patients with high CD8+ cell
tumor infiltration (cutoff median) in patients with re-
sidual tumor (high vs. low: HR = 0.46, 95% CI 0.24-0.88,
p = 0.020), whereas CD8+ cell infiltration was not of
prognostic value in patients without residual tumor (high
vs. low: HR = 0.96, 95% CI 0.57-1.61, p = 0.864). A formal
interaction test for CD8+ cell density and residual tumor
did just not reach significance (p = 0.052).
mRNA expression of CD8 was not correlated with the
density of infiltrating CD8+ cells and had no prognostic
impact
Both mRNA expression data and the immunohistochemis-
try results could be obtained from 158 patients. There was
no correlation between the CD8 gene expression values
and the CD8+ cell density values (R = 0.30, p < 0.001).
Gene expression of CD8 had neither impact on OS nor on
PFS (data not shown).nivariate Multivariable
p HR (CI95%) p
) <0.001 1.26 (1.07-1.48) 0.006
) <0.001 2.18 (1.38-3.45) <0.001
) 0.001 1.87 (1.21-2.88) 0.005
) 0.006 0.82 (0.73-0.92) <0.001
) 0.002 3.34 (1.59-7.04) 0.001
l
nivariate Multivariable
p HR (CI95%) p
) 0.016 1.08 (0.94-1.23) 0.268
) <0.001 2.19 (1.43-3.35) <0.001
) <0.001 1.64 (1.11-2.43) 0.013
) 0.447 0.92 (0.84-1.01) 0.074
) 0.209 1.51 (0.69-3.28) 0.299
Figure 3 Kaplan-Meier curves showing the association between CD8+ cell infiltration and overall survival of patients. CD8+ cell
infiltration (low versus high, cut-off value at median); A: in optimally debulked patients; log-rank test, p = 0.596; B: in patients with residual tumor;
log-rank test, p = 0.055.
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No associations of Ki67 proliferation index (either as
continuous parameter or dichotomized at 5%), CD8+ cell
density, or CD8 gene expression values with the clini-
copathological parameters patients’ age, histological sub-
type, grade, stage, and residual tumor were found (data not
shown). There was a significant correlation between FIGO
stage and residual tumor (p = 0.012). No associations were
found between the other clinicopathological factors (data
not shown).
Discussion
In this study, we found that a small population of ovar-
ian cancer patients with no Ki67+ cells in the primary
tumor had a more than three times higher risk to die
compared to patients with ≥5% Ki67+ cells. Additionally,
an association of CD8+ cell infiltration with improved
OS was observed. Interestingly, these two tumor charac-
teristics were not associated with each other.
To investigate the interaction of tumor cell proliferation
and immunological components in the tumor microenvir-
onment, we analyzed the correlation of Ki67 expression
and tumor infiltrating CD8+ cells. No association was
found, demonstrating that the proliferative ability of tumor
cells is not essential for the infiltration of cytotoxic lym-
phocytes in human ovarian cancer tissue. This is in con-
trast to a previous study reporting a weak association
between Ki67 expression and intraepithelial CD8+ cells
[27]. This discrepancy could be derived from dichotomiz-
ing parameters at different cutoffs. In order to define the
molecular characteristics of the tumor influencing the in-
filtration with leukocytes, various molecules implied in
antigen processing and presentation, costimulation or
leukocyte recruitment should be investigated.
An association of the proliferative status of ovarian tu-
mors with survival has been reported before, using p21-
activted kinase 4 (Pak4) [28] or cell cycle-related kinase
(CCRK) as markers [29]. There are few reports about the
prognostic value of the cell proliferation marker Ki67 inEOC. Rapidly proliferating tumors are expected to cause
poor PFS in patients with residual tumor after cytore-
ductive surgery. We did not find such correlation, sug-
gesting that tumor growth might be controlled by other
mechanisms. Patients with Ki67- tumors had a strongly
reduced overall survival, indirectly indicating that these
tumors may have poor or no response to the chemother-
apeutic drug. All patients included in this study received
platinum-based chemotherapy, in which the platinum
compounds cause crosslinking of DNA and trigger apop-
tosis of the tumor cells. Platinum-compounds, like other
cytotoxic drugs, are believed to gain their specificity by
preferentially killing highly proliferative cells. If residual
tumor cells divide quickly, they will be killed by platinum
and/or paclitaxel compounds when they enter mitosis. In
contrast, slowly growing cells might survive chemotherapy.
Consistently, correlations between clinical complete remis-
sion to first-line chemotherapy and high Ki67 proliferation
index have been reported by other groups [7,30].
If women with Ki67- tumors were identified at the
time of primary surgery, they could be selected for treat-
ment with alternative drugs, such as angiogenesis inhibi-
tors that reduce tumor growth by inhibiting blood vessel
formation rather than targeting rapidly proliferating cells.
Studies comprising larger cohorts of patients with low
Ki67 proliferation indices are needed to validate the results
described in this study.
The importance of tumor infiltrating lymphocytes in
EOC has recently been investigated [8,15]. In accordance
with previous results, we found a correlation of high
CD8+ cell infiltration with improved OS [14-16]. The
lack of prognostic impact on PFS agrees with most studies
of tumor infiltrating lymphocytes in EOC [11]. Comparing
the impact of CD8+ cell density between optimally and
non-optimally debulked patients, only for the latter group
an association trend between high CD8+ cell infiltration
and improved OS was observed, but not for the former
group. In accordance with this rationale, Adams et al.
reported a more likely benefit from surgical debulking for
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filtration and high Ki67 expression [27]. The formal inter-
action test between the factors residual tumor and CD8+
cell infiltration showed non-significance. So, our results
should be regarded as hypothesis generating rather than
hypothesis confirming and need to be validated in an inde-
pendent patient cohort.
mRNA expression as prognostic markers has been
studied in various tumors. For some genes little or no
correlation between protein and mRNA expression was
found [31,32]. In our study, the CD8 gene expression
values obtained from RT-qPCR showed no correlation
with the CD8 data generated by IHC. In addition, the
prognostic impact of CD8+ cells could not be repre-
sented by CD8 gene expression. The differences may be
attributed to the fact that mRNA was obtained from het-
erogeneous tumor tissue samples comprising not only
epithelial tumor tissue, but also stroma and blood ves-
sels, whereas in IHC only tumor infiltrating CD8+ cells
in epithelial tumor areas were analyzed. These results in-
dicate that gene expression measurement may not be
suitable for infiltrating immune cells, at least if tumor
tissues are not micro-dissected.Conclusions
In summary, we observed a significantly reduced survival
of epithelial ovarian cancer patients with Ki67- tumors in-
dicating a poor response to the chemotherapeutic drug.
This small group of patients could benefit from treatment
with alternative drugs. Moreover, a higher number of
tumor infiltrating cytotoxic T lymphocytes was associated
with a better overall survival, presumably due to the stron-
ger effect in non-optimally debulked patients.Abbreviations
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